{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:59:44Z","timestamp":1790510384586,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["TL1TR001858"],"award-info":[{"award-number":["TL1TR001858"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-GM107122"],"award-info":[{"award-number":["R01-GM107122"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21-DK108093"],"award-info":[{"award-number":["R21-DK108093"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jpba.2019.06.033","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T23:32:50Z","timestamp":1562023970000},"page":"618-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Development and validation of a UHPLC-MS\/MS method for measurement of a gut-derived uremic toxin panel in human serum: An application in patients with kidney disease"],"prefix":"10.1016","volume":"174","author":[{"given":"Alexander J.","family":"Prokopienko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Raymond E.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Nolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.jpba.2019.06.033_bib0005","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jpba.2019.06.033_bib0010","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s11255-013-0407-1","article-title":"The risk of atherosclerosis in patients with chronic kidney disease","volume":"45","author":"Olechnowicz-Tietz","year":"2013","journal-title":"Int. Urol. Nephrol."},{"issue":"10","key":"10.1016\/j.jpba.2019.06.033_bib0015","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.2215\/CJN.12691117","article-title":"Microbiome and cardiovascular disease in CKD","volume":"13","author":"Jovanovich","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.jpba.2019.06.033_bib0020","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1681\/ASN.2011121175","article-title":"G. European uremic toxin work, normal and pathologic concentrations of uremic toxins","volume":"23","author":"Duranton","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.jpba.2019.06.033_bib0025","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.ajkd.2015.09.027","article-title":"Role of the gut microbiome in Uremia: a potential therapeutic target","volume":"67","author":"Ramezani","year":"2016","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"10.1016\/j.jpba.2019.06.033_bib0030","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2215\/CJN.08790817","article-title":"Extended duration nocturnal hemodialysis and changes in plasma metabolite profiles","volume":"13","author":"Kalim","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.jpba.2019.06.033_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10010033","article-title":"Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update","volume":"10","author":"Vanholder","year":"2018","journal-title":"Toxins (Basel)"},{"issue":"2","key":"10.1016\/j.jpba.2019.06.033_bib0040","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/ATVBAHA.114.304674","article-title":"Associations of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris","volume":"35","author":"Pedersen","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.jpba.2019.06.033_bib0045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11255-012-0258-1","article-title":"An update on uremic toxins","volume":"45","author":"Neirynck","year":"2013","journal-title":"Int. Urol. Nephrol."},{"issue":"5","key":"10.1016\/j.jpba.2019.06.033_bib0050","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jvs.2017.09.029","article-title":"Plasma microbiome-modulated indole- and phenyl-derived metabolites associate with advanced atherosclerosis and postoperative outcomes","volume":"68","author":"Cason","year":"2018","journal-title":"J. Vasc. Surg."},{"issue":"4","key":"10.1016\/j.jpba.2019.06.033_bib0055","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1681\/ASN.2013080905","article-title":"The gut microbiome, kidney disease, and targeted interventions","volume":"25","author":"Ramezani","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.jpba.2019.06.033_bib0060","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00216-012-6636-9","article-title":"A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients","volume":"405","author":"Boelaert","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2019.06.033_bib0065","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.aca.2016.06.057","article-title":"A liquid chromatography - tandem mass spectrometry method to measure a selected panel of uremic retention solutes derived from endogenous and colonic microbial metabolism","volume":"936","author":"de Loor","year":"2016","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jpba.2019.06.033_bib0070","article-title":"Measuring serum total and free indoxyl sulfate and p-cresyl sulfate in chronic kidney disease using UPLC-MS\/MS","author":"Chia-Ni Lin","year":"2018","journal-title":"J Food Drug Anal In Press"},{"key":"10.1016\/j.jpba.2019.06.033_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2017.10.009","article-title":"Simultaneous quantitative analysis of uremic toxins by LC-MS\/MS with a reversed-phase\/cation-exchange\/anion-exchange tri-modal mixed-mode column","volume":"1068-1069","author":"Kanemitsu","year":"2017","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"11","key":"10.1016\/j.jpba.2019.06.033_bib0080","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/bmc.3753","article-title":"LC-MS\/MS method for simultaneous determination of serum p-cresyl sulfate and indoxyl sulfate in patients undergoing peritoneal dialysis","volume":"30","author":"Shu","year":"2016","journal-title":"Biomed. Chromatogr."},{"issue":"7","key":"10.1016\/j.jpba.2019.06.033_bib0085","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00216-012-5929-3","article-title":"Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography\/tandem mass spectrometry and their effects on endothelial ROS production","volume":"403","author":"Itoh","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"issue":"10","key":"10.1016\/j.jpba.2019.06.033_bib0090","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1007\/s00216-011-5436-y","article-title":"Quantitative profiling of tryptophan metabolites in serum, urine, and cell culture supernatants by liquid chromatography-tandem mass spectrometry","volume":"401","author":"Zhu","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"issue":"29","key":"10.1016\/j.jpba.2019.06.033_bib0095","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/j.jchromb.2010.09.006","article-title":"Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography\/tandem mass spectrometry","volume":"878","author":"Kikuchi","year":"2010","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"2","key":"10.1016\/j.jpba.2019.06.033_bib0100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1570-0232(02)00572-X","article-title":"Quantitation of tryptophan, kynurenine and kynurenic acid in human plasma by capillary liquid chromatography-electrospray ionization tandem mass spectrometry","volume":"780","author":"Amirkhani","year":"2002","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2019.06.033_bib0105","doi-asserted-by":"crossref","DOI":"10.1021\/acs.analchem.8b05884","article-title":"Ultrahigh-performance liquid chromatography tandem mass spectrometry with electrospray ionization quantification of tryptophan metabolites and markers of gut health in serum and plasma-application to clinical and epidemiology cohorts","author":"Whiley","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2019.06.033_bib0110","series-title":"Guidance for Industry - Bioanalytical Method Validation","year":"2018"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519307241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519307241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T01:05:11Z","timestamp":1610154311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519307241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":22,"alternative-id":["S0731708519307241"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.06.033","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a UHPLC-MS\/MS method for measurement of a gut-derived uremic toxin panel in human serum: An application in patients with kidney disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}